SynZyme is a biopharmaceutical company dedicated to developing drugs for the treatment of life threatening disruption of blood flow. SynZyme’s platform technology of catalytic caged nitric oxide (cNO), aka nitroxide, has enabled the development of drugs that enhance blood flow in critical organs and treat the toxicity of acute hemoglobin release, excessive superoxide production and nitric oxide depletion. Based on years of research, SynZyme has developed a drug pipeline of cNO modified macromolecules, in particular albumin and hemoglobin, as multifunctional neurovascular protective, hemodynamic stabilizing and antioxidative drugs for unmet medical needs in critical care medicine. With these drugs, SynZyme is targeting major diseases like hemorrhagic and ischemic stroke, traumatic brain injury, shock, and sickle cell disease. These drugs are also being developed as a means to increase the efficacy of cancer drugs treating solid tumors by opening up the hypoxic core to blood circulation. Additionally, SynZyme is developing an artificial blood for unmet medical needs in transfusion medicine.
SynZyme expects to fund the development of these drugs through multiple exploratory clinical trials in partnership with NIH/DOD/FDA and multinational pharmaceutical companies leading to global commercialization of these life saving drugs.